DBV Technologies SA (NASDAQ:DBVT)

1.95
Delayed Data
As of Sep 18
 -0.03 / -1.52%
Today’s Change
1.90
Today|||52-Week Range
13.49
-81.78%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$214.0M

Company Description

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. It focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Montrouge, France.

Contact Information

DBV Technologies SA
177-181, avenue Pierre Brossolette
Montrouge Ile-de-france 92120
P:(315) 542-7878
Investor Relations:
(212) 271-0740

Employees

Shareholders

Mutual fund holders6.01%
Other institutional37.46%
Individual stakeholders--

Top Executives

Daniel TasséChief Executive Officer & Executive Director
Ramzi BenamarChief Financial Officer
Bertrand DupontChief Technology Officer
Hugh A. SampsonChief Scientific Officer
Pharis MohideenChief Medical Officer